173 related articles for article (PubMed ID: 25483483)
1. A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children.
Ambrose CS; Chen X; Kumar VR
Hum Vaccin Immunother; 2014; 10(10):2785-8. PubMed ID: 25483483
[TBL] [Abstract][Full Text] [Related]
2. Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.
Forbes ML; Kumar VR; Yogev R; Wu X; Robbie GJ; Ambrose CS
Hum Vaccin Immunother; 2014; 10(10):2789-94. PubMed ID: 25483663
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.
Ordóñez JE; Huertas VM
BMC Infect Dis; 2024 Apr; 24(1):418. PubMed ID: 38641577
[TBL] [Abstract][Full Text] [Related]
4. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Safety of Palivizumab for the Prevention of Serious Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus: A Systematic Review.
Gonzales T; Bergamasco A; Cristarella T; Goyer C; Wojdyla M; Oladapo A; Sawicky J; Yee J; Moride Y
Am J Perinatol; 2024 May; 41(S 01):e1107-e1115. PubMed ID: 36452969
[TBL] [Abstract][Full Text] [Related]
6. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.
Fenton C; Scott LJ; Plosker GL
Paediatr Drugs; 2004; 6(3):177-97. PubMed ID: 15170364
[TBL] [Abstract][Full Text] [Related]
7. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.
Narayan O; Bentley A; Mowbray K; Hermansson M; Pivonka D; Kemadjou EN; Belsey J
J Med Econ; 2020 Dec; 23(12):1640-1652. PubMed ID: 33107769
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for hospitalisation due to respiratory syncytial virus infection in children receiving prophylactic palivizumab.
Chida-Nagai A; Sato H; Sato I; Shiraishi M; Sasaki D; Izumi G; Yamazawa H; Cho K; Manabe A; Takeda A
Eur J Pediatr; 2022 Feb; 181(2):539-547. PubMed ID: 34417646
[TBL] [Abstract][Full Text] [Related]
9. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
;
Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection.
Gutfraind A; Galvani AP; Meyers LA
JAMA Pediatr; 2015 Apr; 169(4):341-8. PubMed ID: 25706618
[TBL] [Abstract][Full Text] [Related]
11. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
12. Effect of Prophylactic Palivizumab on Admission Due to Respiratory Syncytial Virus Infection in Former Very Low Birth Weight Infants with Bronchopulmonary Dysplasia.
Han YM; Seo HJ; Choi SH; Jung YJ; Ahn SY; Yoo HS; Sung SI; Shim JW; Lee YK; Ko SY; Shin SM; Hwang JH; Lee JH; Choi BM; Kim ES; Jeon JH; Kim SS; Chang YS; Park WS
J Korean Med Sci; 2015 Jul; 30(7):924-31. PubMed ID: 26130956
[TBL] [Abstract][Full Text] [Related]
13. A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation.
Turti TV; Baibarina EN; Degtiareva EA; Keshishyan ES; Lobzin YV; Namazova-Вaranova LS; Prodeus AP; Gudkov KM; Kruglova AI; Schulz GA; Notario GF
BMC Res Notes; 2012 Sep; 5():484. PubMed ID: 22943074
[TBL] [Abstract][Full Text] [Related]
14. An epidemiological investigation of high-risk infants for Respiratory Syncytial Virus infections: a retrospective cohort study.
Servadio M; Finocchietti M; Vassallo C; Cipelli R; Heiman F; Di Lucchio G; Oresta B; Addis A; Belleudi V
Ital J Pediatr; 2024 Mar; 50(1):56. PubMed ID: 38528568
[TBL] [Abstract][Full Text] [Related]
15. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.
Pediatrics; 1998 Nov; 102(5):1211-6. PubMed ID: 9794957
[TBL] [Abstract][Full Text] [Related]
16. Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high-risk infants.
Stiboy E; Chan M; Islam MS; Saravanos GL; Lui K; Jaffe A; Homaira N
Pediatr Pulmonol; 2023 Apr; 58(4):1210-1220. PubMed ID: 36748923
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study.
Manzoni P; Paes B; Lanctôt KL; Dall'Agnola A; Mitchell I; Calabrese S; Maule M; Girardi E; Harimoto T; Li A
Pediatr Infect Dis J; 2017 Jan; 36(1):2-8. PubMed ID: 27649365
[TBL] [Abstract][Full Text] [Related]
18. Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis.
Krilov LR; Masaquel AS; Weiner LB; Smith DM; Wade SW; Mahadevia PJ
BMC Pediatr; 2014 Oct; 14():261. PubMed ID: 25308481
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ
J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495
[TBL] [Abstract][Full Text] [Related]
20. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
Meissner HC; Long SS;
Pediatrics; 2003 Dec; 112(6 Pt 1):1447-52. PubMed ID: 14654628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]